About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
A New List of 503B Outsourcing Facilities Offers No Guarantee of Anything
Compounders who prepare nonpatient-specific prescriptions have been slow to sign up for a new FDA program meant to serve as a de facto “Good Housekeeping” seal of approval. Meanwhile, inspectors are turning up problems wherever they go.
Considerations for the Appropriate Use of Skeletal Muscle Relaxants for the Management Of Acute Low Back Pain
For patients with low back pain, skeletal muscle relaxants are often initiated after failure of first-line analgesics. However, these medications (reviewed in this article) are controversial alternatives that carry risks of adverse effects and increased cost.
Corey Witenko, PharmD, BCPS; Robin Moorman-Li, PharmD, BCACP; Carol Motycka, PharmD, BCACP; Kevin Duane, PharmD; Juan Hincapie-Castillo, PharmD; Paul Leonard, PharmD; and Christopher Valaer, PharmD
An array of natural substances purported to possess disease-modifying qualities for osteoarthritis are designated as “dietary supplements” and thus avoid rigorous FDA regulation. Substantial scientific evidence for the efficacy of these agents is elusive.
Philip J. Gregory, PharmD; and Chris Fellner
An integrated health care system used an online database that captured pharmacists’ reports of medication errors and an algorithm that helped classify and prioritize the information to identify patterns and improve safety outcomes.
Alan Polnariev, PharmD, MS, CGP
The American Association for Cancer Research meeting included reports on new agents for breast cancer and melanoma. The American Psychiatric Association meeting offered updates on treatments for bipolar depression, autism, and depression.
Matthew Grissinger, RPh, FaScP
FDA approvals, drug indications, and updates
Apremilast (Otezla) for active psoriatic arthritis, omalizumab (Xolair) for chronic idiopathic urticaria, and grass pollen allergen extract (Oralair) for grass pollen-induced allergic rhinitis with or without conjunctivitis
Marvin M. Goldenberg, PhD, RPh, MS